DOI 10.1016/j.bioadv.2026.215070
Engineering a tumor-homing ZIF-8 nanoplatform for safe and synergistic immunotherapy of osteosarcoma.
Аннотация
Osteosarcoma, a highly heterogeneous tumor with an immunosuppressive microenvironment, remains therapeutically refractory because of the dominance of M2-polarized macrophages and myeloid-derived suppressor cells (MDSCs) and the lack of effective immune activation. In this study, we developed a tumor-targeted, pH-responsive nanoplatform (OTP@ZIF-8) based on a ZIF-8 scaffold co-loaded with an anti-CD47 monoclonal antibody (mAb) and hydralazine and functionalized with a phage display-identified osteosarcoma-homing peptide. Hydralazine suppressed MDSC-mediated immunosuppression by inhibiting methylglyoxal biosynthesis, while anti-CD47 mAb enhanced macrophage phagocytosis by blocking the "don't-eat-me" signal. Peptide-guided targeting combined with stimuli-responsive release enabled selective intratumoral accumulation, reduced systemic toxicity, and eliminated anti-CD47-induced hemolysis. In vitro and in vivo, OTP@ZIF-8 synergistically inhibited tumor growth by remodeling the immunosuppressive microenvironment, decreasing M2-polarized macrophages and MDSCs while promoting phagocytosis and T-cell activation. This study offers a rational and multifunctional strategy for precision immunotherapy against highly heterogeneous tumors.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.